We are live on
!
Find out more
FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$3.89B
1-Year Est. Return
201.1%
This Fund
S&P 500
This Quarter
Est. Return
+37.43%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$239M
(+23%)
Cap. Flow
+$108M
Cap. Flow
% of AUM
8.34%
Top 10 Holdings %
Top 10 Hldgs %
67.1%
Holding
47
New
6
Increased
10
Reduced
7
Closed
4
Top Buys
| 1 |
Rhythm Pharmaceuticals
RYTM
|
+$35.2M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
+$24.6M |
| 3 |
ALLK
Allakos
ALLK
|
+$20.1M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$17.7M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$13.9M |
Top Sells
| 1 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$47.9M |
| 2 |
Viridian Therapeutics
VRDN
|
+$11.3M |
| 3 |
Vaxcyte
PCVX
|
+$6.08M |
| 4 |
Krystal Biotech
KRYS
|
+$5.56M |
| 5 |
Passage Bio
PASG
|
+$2.47M |
Sector Composition
| 1 | Healthcare | 98.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HLVX
1
DELISTED
HilleVax
HLVX
| $167M | 12.84% |
9,758,359
+472,677
| +5% | +$6.87M |
|
2
Arcutis Biotherapeutics
ARQT
$3.46B
| $166M | 12.78% |
8,684,232
+250,000
| +3% | +$5.66M |
|
|
3
Phathom Pharmaceuticals
PHAT
$878M
| $93.2M | 7.17% |
8,407,152
+2,579,737
| +44% | +$24.6M |
|
|
KDNY
4
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $83.9M | 6.46% |
4,265,559
+670,533
| +19% | +$13.4M |
|
5
Syndax Pharmaceuticals
SNDX
$2.04B
| $82M | 6.31% |
3,412,838
+217,435
| +7% | +$4.88M |
|
6
Mirum Pharmaceuticals
MIRM
$7.19B
| $80.4M | 6.19% |
3,827,781
+260,869
| +7% | +$6.28M |
|
|
7
Krystal Biotech
KRYS
$10.2B
| $71M | 5.47% |
1,018,388
-77,019
| -7% | -$5.56M |
|
|
8
Rhythm Pharmaceuticals
RYTM
$7.28B
| $46.4M | 3.57% |
+1,894,000
| New | +$35.2M |
|
|
IMGO
9
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $44.7M | 3.44% |
2,971,274
| – | – |
|
|
10
Vaxcyte
PCVX
$7.99B
| $37.1M | 2.86% |
1,547,405
-240,000
| -13% | -$6.08M |
|
11
Cogent Biosciences
COGT
$6.49B
| $30.9M | 2.38% |
2,074,154
-20,000
| -1% | -$274K |
|
12
Tarsus Pharmaceuticals
TARS
$2.57B
| $30.6M | 2.36% |
1,787,527
| – | – |
|
|
ALLK
13
DELISTED
Allakos
ALLK
| $29.3M | 2.26% |
+4,792,000
| New | +$20.1M |
|
14
Crinetics Pharmaceuticals
CRNX
$8.88B
| $27.8M | 2.14% |
1,414,823
| – | – |
|
|
TCDA
15
DELISTED
Tricida, Inc. Common Stock
TCDA
| $26.7M | 2.06% |
2,549,671
+467,578
| +22% | +$5.11M |
|
16
AnaptysBio
ANAB
$1.6B
| $23M | 1.77% |
899,700
| – | – |
|
|
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
| $22.8M | 1.76% |
1,572,192
| – | – |
|
|
ALPN
18
DELISTED
Alpine Immune Sciences Inc
ALPN
| $21.5M | 1.66% |
2,985,757
| – | – |
|
|
VRNA
19
DELISTED
Verona Pharma
VRNA
| $21.5M | 1.65% |
+2,099,541
| New | +$17.7M |
|
|
FLACU
20
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
| $15.2M | 1.17% |
1,501,000
| – | – |
|
|
MRUS
21
DELISTED
Merus
MRUS
| $15M | 1.15% |
746,479
+72,500
| +11% | +$1.73M |
|
|
22
Acadia Pharmaceuticals
ACAD
$4.42B
| $14M | 1.08% |
+857,338
| New | +$13.9M |
|
23
Replimune Group
REPL
$754M
| $13.9M | 1.07% |
806,267
| – | – |
|
|
GRTS
24
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $13.5M | 1.04% |
5,237,348
| – | – |
|
25
Arvinas
ARVN
$517M
| $12.7M | 0.98% |
285,331
| – | – |
|
Similar funds
GAMH
MSI
CCM
TFM
SCM
MIM
AA
DACG